🔬 The expansion will include the construction of a new site in Europe and capacity expansions in its Colorado facility.
💊 The investment aims to meet the increasing demand for GLP-1 peptides used in diabetes and obesity treatments.
💪 CordenPharma aims to become a market leader in peptide services and reach a sales target of €1bn by 2028.
Introduction:
CordenPharma, a leading contract development and manufacturing organization (CDMO), has announced plans to invest €900m over the next three years to expand its peptide platform. This investment will involve expanding production capacity at its Colorado site in the US and constructing a new greenfield site in Europe. The expansions will enable CordenPharma to meet the increasing demand for peptide manufacturing and solidify its position as a market leader in the supply of peptide services.
- CordenPharma plans to invest €900m over the next three years to expand its peptide platform.
- The expansion will involve increasing production capacity at the Colorado site and constructing a new greenfield site in Europe.
- The expansion will enable CordenPharma to meet the growing demand for peptide manufacturing.
- CordenPharma aims to achieve €1bn in sales for its peptide platform by 2028.
- The investment reinforces CordenPharma’s position as a market leader in the integrated supply of peptide services.
Conclusion:
CordenPharma’s €900m investment in expanding its peptide platform demonstrates the company’s commitment to meeting the increasing demand for peptide manufacturing. The expansion plans will enhance CordenPharma’s production capacity and enable it to provide high-quality peptide services to the pharmaceutical industry. This investment positions CordenPharma as a market leader in the supply of peptide services and supports the company’s goal of achieving €1bn in sales for its peptide platform by 2028. The expansion also highlights the growing importance of peptides in the pharmaceutical industry and the need for advanced manufacturing capabilities to meet market demand.
